Loading news...
PolyPid Ltd. (NASDAQ: PYPD - Get Free Report) has received an average recommendation of "Moderate Buy" from the six research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year price target among brokers
FDA Grants $4. 3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations
PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in two upcoming investor conferences taking place during March 2026.
PolyPid (NASDAQ: PYPD) said 2025 marked a "pivotal year" as the company completed its SHIELD II Phase 3 trial and moved D-PLEX100 into the final stages of regulatory preparation, while also advancing U.S. commercial partnership discussions ahead of a planned new drug application submission in early 2026. Regulatory path: FDA supports rolling NDA submission Chief Executive
PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript
The Company is in Advanced Stage s of Commercial U.S. Partner ship Discussions for D-PLEX₁₀₀
PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026.
Appointment Enhances PolyPid's Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application Submission Appointment Enhances PolyPid's Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application Submission
PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript
PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application (“NDA”) meeting minutes from the U.S. Food and Drug Administration (“FDA”) supporting the NDA submission of D-PLEX100, the Company's lead product candidate for the prevention of surgical site infections in abdominal colorectal surgeries.
Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX₁₀₀ Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX₁₀₀
PolyPid Ltd. ( PYPD ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Dikla Akselbrad - CEO & Director Ori Warshavsky - Chief Operating Officer - US Jonny Missulawin - Chief Financial Officer Conference Call Participants Yehuda Leibler Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Brandon Folkes - H.C.
Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026
PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company focused on improving surgical outcomes, today announced that D-PLEX₁₀₀, the company's lead candidate, has been named "Therapeutics Solution of the Year" by BioTech Breakthrough , a leading independent market intelligence organization which evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.
PolyPid Ltd. (NASDAQ: PYPD - Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 57,800 shares, a growth of 61.5% from the September 30th total of 35,800 shares. Based on an average daily volume of 62,200 shares, the
PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world's leading surgical conferences The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world's leading surgical conferences
PETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that management will be presenting at the Lytham Partners Fall 2025 Virtual Investor Conference on September 30, 2025. Additionally, management will be participating in the upcoming 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025.
PETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd.
PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-9, 2025, at the Lotte New York Palace Hotel, New York City.